Imaging the earliest stages of Alzheimer's disease

Current Alzheimer Research

Volumn 3, Issue 5, 2006, Pages 529-539

  Wu, William ^b   Small, Scott A ^a  

^a PH # 19 ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; DEOXYHEMOGLOBIN;

ALZHEIMER DISEASE; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; BRAIN DYSFUNCTION; BRAIN MAPPING; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; ENERGY METABOLISM; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HIPPOCAMPUS; HUMAN; INTERMETHOD COMPARISON; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN BLOOD LEVEL; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; BRAIN; BRAIN MAPPING; DIAGNOSTIC IMAGING; HUMANS;

EID: 33846114647     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720506779025161     Document Type: Review

References (105)

1. Jacobs DM, Sano M, Dooneief G, Marder K, Bell KL and Stern Y. Neuropsychological detection and characterization of preclinical Alzheimer's disease [comment] [see comments]. Neurology 45: 957-962 (1995).
2. Masur DM, Sliwinski M, Lipton RB, Blau AD and Crystal HA. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons [see comments]. Neurology 44: 1427-1432 (1994).
3. Zhao X, Lein ES, He A, Smith SC, Aston C and Gage FH. Transcriptional profiling reveals strict boundaries between hippocampal subregions. J Comp Neurol 441 : 187-196 (2001).
4. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. J Am Med Assoc, 2120-2127 (2001).
5. Simic G, Kostovic I, Winblad B and Bogdanovic N. Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. J Comp Neurol 379 : 482-494 (1997).
6. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW and Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 58 : 1395-1402 (2001).
7. Fukutani Y, Cairns NJ, Shiozawa M, Sasaki K, Sudo S, Isaki K, et al. Neuronal loss and neurofibrillary degeneration in the hippocampal cortex in late-onset sporadic Alzheimer's disease. Psychiatry Clin Neurosci 54 : 523-529 (2000).
8. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60 : 1495-1500(2003).
9. Braak H and Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 165 : 3-12(1996).
10. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry, 24-35 (2002).
11. Schonheit B, Zarski R and Ohm TG. Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol Aging 25: 697-711(2004).
12. West MJ, Kawas CH, Stewart WF, Rudow GL, and Troncoso JC. Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol Aging 25: 1205-1212(2004).
13. West MJ. Regionally specific loss of neurons in the aging human hippocampus. Neurobiol Aging 14 : 287-293 (1993).
14. Tanzi RE. Tangles and neurodegenerative disease - a surprising twist. N Engl J Med 353 :1853-1855 (2005).
15. Small SA, Nava AS, Perera GM, Delapaz R and Stern Y. Evaluating the function of hippocampal subregions with high-resolution MRI in Alzheimer's disease and aging [In Process Citation]. Microsc Res Tech 51 : 101-108(2000).
16. Small SA. Quantifying cerebral blood flow: regional regulation with global implications. J Clin Invest 114 : 1046-1048 (2004).
17. Small S, Wu E, Bartsch D, Lacefield C, DeLaPaz R, Mayeux R, et al. Imaging physiologic dysfunction of individual hippocampal subregions in humans and genetically modified mice. Neuron 653-664 (2000).
18. Erecinska M and Silver IA. ATP and brain function. J Cereb Blood Flow Metab 9, 2-19 (1989).
19. Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M and Terry R. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett 174 : 67-72(1994).
20. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20: 4050-4058 (2000).
21. Rombouts SA, Barkhof F, Veltman DJ, Machielsen WC, Witter MP, Bierlaagh MA, et al. Functional MR imaging in Alzheimer's disease during memory encoding. AJNR Am J Neuroradiol 21, 1869-1875 (2000).
22. Silverman DH, Small GW, Phelps ME. Clinical value of neuroimaging in the diagnosis of dementia. Sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease. Clinical Positron Imaging, 119-130 (1999).
23. Sperling R.. Functional MRI studies in early Alzheimers disease. In International Conference on Alzheimer's disease and Related Disorders: Stocholm, Sweden (2002).
24. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA and Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A 98, 676-682 (2001).
25. Davis TL, Kwong KK, Weisskoff RM, Rosen BR. Calibrated functional MRI: mapping the dynamics of oxidative metabolism. Proc Natl Acad Sci 1834-1839 (1998).
26. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, et al. The 14-C deoxyglucose method for the measurement of local glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 897-916 (1977).
27. Phelps ME, Kuhl DE, Mazziotta JC. Metabolic mapping of the brain's response to visual stimulation: studies in humans. Science 1445-1448 (1981).
28. Greenberg JH, Reivich M, Alavi A, Hand P, Rosenquist A, Rintelmann W, et al. Metabolic imaging of functional activity in human subjects with the 18-F fluorodeoxyglucose technique. Science 678-680 (1981).
29. Benson DF, Kuhl DE, Hawkins RA, Phelps ME, Cummings JL, Tsai SY. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol 711-714 (1983).
30. Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, Di Chiro, et al. Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology 961-965 (1983).
31. Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with (18F) fluoro-deoxyglucose. J Comput Assist Tomogr 590-598 (1983).
32. Duara R, Grady C, Haxby J, Sundaram M, Cutler NR, Heston L, et al. Positron emission tomography in Alzheimer's disease. Neurology 879-887(1986).
33. Silverman DH. Brain 18F-FDG PET in the Diagnosis of Neurodegenerative Dementias: Comparison with Perfusion SPECT and with Clinical Evaluations Lacking Nuclear Imaging. Journal of Nuclear Medicine 45: 594-607 (2004).
34. Devous Sr MD. Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies. Eur J Nucl Med 29: 1685-1696 (2002).
35. Mielke R, Peitrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, et al. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med 1052-1060(1994).
36. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-18F fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). PNAS 98 : 10966-10971 (2001).
37. Mazziotta JC, Frackowiak RS, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. Semin Nucl Med 233-246 (1992).
38. Fukuyama H, Ogawa M, Yamauchi H, Yamaguchi S, Kimura J, Yonekura Y, et al. Altered cerebral energy metabolism in Alzheimer's disease. J Nucl Med 35, 1-6 (1994).
39. Kumar A, Schapiro MB, Grady C, Haxby JV, Wagner E, Salerno JA, et al. High-resolution PET studies in Alzheimer's disease. Neuropsychopharmacology 4: 35-46 (1991).
40. Rapoport SI. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis - a critical review. Cerebrovascular & Brain Metabolism Reviews 3: 297-335(1991).
41. Grady CL, Haxby JC, Schapiro MB, Gonzalez-Aviles A, Kumar A, Bali MJ, et al. Subgroups in dementia of the Alzheimer type identified using positron emission tomography. J Neuropsychiatry Clin Neurosci 373-384 (1990).
42. Mielke R, Schroder R, Fink GR, Kessler J, Herholz K, Heiss WD. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol 174-179 (1996).
43. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 85-94 (1997).
44. Hirono N, Hashimoto M, Ishii K, Kazui H, Mori E. One-Year Change in Cerebral Glucose Metabolism in Patients with Alzheimer's Disease. J Neuropsychiatry Clin Neurosci 16 : 488-492 (2004).
45. Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ, et al. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 454-461(1996).
46. Kuhl D, Small GW, Riege WH, Fujikawa DG, Ashford JW, Metter EJ, et al. Cerebral metabolic patterns before the diagnosis of probable Alzheimer's disease. AJ Cereb Blood Flow Metab, 406 (1987).
47. Heiss WD, Szelies B, Kessler J, Herholz K. Abnormalities of energy metabolism in Alzheimer's disease studied with PET. Ann NY Acad Sci 65-71 (1991).
48. de Leon MJ, Ferris SH, George AE, Reisberg B, Christman DR, Kricheff II, et al. Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease. J Cereb Blood Flow Metab, 391-394 (1983).
49. Haxby J. Resting state regional cerebral metabolism in dementia of the Alzheimer type. In Positron Emission Tomography in Dementia, R. Duara, ed. (New York: Wiley-Liss, Inc.), pp. 93-116 (1990).
50. Barbas H and Blatt GJ. Topographically specific hippocampal projections target functionally distinct prefrontal areas in the rhesus monkey. Hippocampus 5, 511-533 (1995).
51. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E. N Engl J Med 752-758 (1996).
52. Silverman DH, Chang CY, Cummings J, Small GW, Lu CS, Kung de Aburto MA, et al. Neuroimaging in evaluation of dementia: regional brain metabolism and long-term clinical outcomes. Clin Positron Imaging, 119-130 (2000).
53. Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, et al. Metabolic impairment of association cortex predicts progression in Alzheimer's disease: a prospective multicenter positron emission tomography (PET) study. Eur J Neurol (1998).
54. Kennedy AM, Frackowiak RSJ, Newman SK, Bloomfield PM, Seaward J, Roques P, et al. Deficits in cerebral glucose-metabolism demonstrated by positron emission tomography in individuals at risk of Alzheimer's disease. Neurosci Lett, 17-20 (1995).
55. Kippenhan SJ, Barker VW, Pascal S, Nagel J. and Duara R. Evaluation of a neural-network classifier for PET scans of normal and Alzheimer's disease subjects. J Nucl Med 1459-1467 (1992)..
56. Lenzi G. Brain work: function, metabolism and blood flow. Archives italiennes de biologie 189-200 (1982).
57. Frackowiak R, Pozzilli C, Legg NJ, Du Boulay GH, Marshall J, Lenzi GL, et al. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain, 753-778(1981).
58. Ohyama M, Senda M, Ishiwata K, Kitamura S, Mishina M, Ishii K, et al. Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF. Ann Nucl Med 13: 309-315 (1999).
59. Sakomoto S. Studies of cerebral blood flow and metabolism in patients with senile dementia of the Alzheimer's type and diagnostic evaluation of the dementing illnesses by positron emission tomography. Nippon Ika Daigaku Zasshi 222-234 (1990).
60. Becker JT, Mintun MA, Aleva K, Wiseman MB, Nichols T, De-Kosky ST, et al. Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer's disease. Neurology 46 : 692-700 (1996).
61. Tohgi H, Yonezawa H, Takahashi S, Sato N, Kato E, Kudo M, et al. Cerebral blood flow and oxygen metabolism in senile dementia of Alzheimer's type and vascular dementia with deep white matter changes. Neuroradiology, 131-137(1998).
62. Nagata K, Maruya H, Yuya H, Terashi H, Mito Y, Kato, et al. Can PET data differentiate Alzheimer's disease from vascular dementia? Ann NY Acad Sci, 252-261 (2000).
63. Ishii K, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Mori E. Paradoxical hippocampus perfusion in mild-to-moderate Alzheimer's disease. J Nucl Med 293-298(1998).
64. Ishii K, Sasaki M, Matsui M, Sakamoto S, Yamaji S, Hayashi N. A diagnostic method for suspected Alzheimer's disease using H215O positron emission tomography perfusion Z score. Neuroradiology 787-794 (2000).
65. Jobst KA, Smith AD, Barker CS, Wear A, King EM, Smith A, et al (1992). Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease. Neurosurg Psychiatry, 190-194.
66. Holman BL, Johnson KA, Gerada B, Carvalho PA, Satlin A. The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT. J Nucl Med 181-185 (1992).
67. Motomura N, Seo T. Lateral hemispheric asymmetries in senile dementia of Alzheimer's type (SDAT) assessed by I-123 IMP SPECT imaging: a preliminary report. Int J Neurosci, 1-3 (1992).
68. Jagust W, Thisted R, Devous MD, Sr, Van Heertum R, Mayberg H, Jobst K, et al. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology 56 : 950-956 (2001).
69. Johnson KA, Jones K, Holman BL, Becker JA, Spiers PA, Satlin A, et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1563-1571 (1998).
70. Albert MR. Detection of very early Alzheimer disease through neuroimaging. Associ Dis Alz Disord S63-65 (2003).
71. Bradley K, O'Sullivan VT, Soper NDW, Nagy Z, King EM, Smith A, et al. Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain, 1772-1781 (2002).
72. Callen DJA, Black SE, Caldwell CB. Limbic system perfusion in Alzheimer's disease measured by MRI-coregistered HMPAO SPET. Eur J Nucl Med 29, 899-906(2002).
73. Braak H and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82: 239-259 (1991).
74. Braak H and Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18: 351-357 (1997).
75. El Fakhri G, Kijewski MF, Johnson KA, Syrkin G, Killiany RJ, Becker JA, et al. MRI-guided SPECT perfusion measures and volumetric MRI in prodromal Alzheimer disease. Arch Neurol 60 : 1066-1072(2003).
76. Herholz K, Schopphoff H, Schmidt M, Mielke R, Eschner W, Scheidnauer K, et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. Journal of Nuclear Medicine 21-26(2002).
77. Masterman DL, Mendez MF, Fairbanks LA. and Cummings JL. Sensitivity specificity and positive predictive value of technetium 99m-HMPAO SPECT in discriminating dementia from other dementias. J Geretr Psychiatry Neurol, 15-21(1997).
78. Karbe H, Kertesz A, Davis J, Kemp BJ, Prato FS. and Nicholson RL. Quantification of functional deficit in Alzheimer's disease using a computer-assisted mapping program for 99mTc-HMPAO SPECT. Neuroradiology 36 : 1-6 (1994).
79. Calamante F, Thomas DL, Pell GS, Wiersma JA, Turner R. Measuring cerebral blood flow using magnetic resonance imaging techniques. J Cereb Blood Flow Metab 19: 701-735 (1999).
80. Alsop DC and Detre JA. Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow. J Cereb Blood Flow Metab 16, 1236-1249 (1996).
81. Sandson TA, O'Connor M, Sperling RA, Edelman RR. and Warach S. Noninvasive perfusion fMRI in Alzheimer's disease: a preliminary report. Neurology 1339-1342 (1996).
82. Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Am Neurol, 93-100 (2000).
83. Johnson NA, Jahng G, Weiner MW, Miller BL, Chui HC, Jagust WJ, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: Initial Experience. Neuroradiology, 851-859 (2005).
84. Belliveau JW, Rosen BR, Kantor HL, Rzedzian RR, Kennedy DN, McKinstry RC, et al. Functional cerebral imaging by susceptibility contrast. Magn Reson Med 538-546(1990).
85. D'Esposito M, Zarahn E, Aguirre GK, Rypma B. The effect of normal aging on the coupling of neural activity to the BOLD hemodynamic response. NeuroImage, 6-14(1999).
86. Harris GJ, Lewis RF, Satlin A, English CD, Scott TM, Yurgelun-Todd DA, et al. Dynamic susceptibility contrast MRI of regional cerebral blood volume in Alzheimer's disease. Am J Psychiatr 153, 721-724 (1996).
87. Harris GJ, Lewis RF, Satlin A, English CD, Scott TM, Yurgelun-Todd DA, et al. Dynamic susceptibility contrast MR imaging of regional blood volume in Alzheimer disease: a promising alternative to nuclear medicine. Am J Neuroradiol, 1727-1732 (1998).
88. Renshaw PF, English CD, Satlin AS, Lewis RF, Harris GJ. Comparison of brain SPECT and dynamic susceptibility contrast MR imaging in Alzheimer disease. In RSNA, vol. Scientific Program of the RSNA. Paper #13 (1996).
89. Bozzao A, Floris R, Baviera ME, Apruzzese A, Simonetti G. Diffusion and perfusion MR imaging in cases of Alzheimer's disease. Am J Neuroradiol, 1030-1036 (2001).
90. O'Mahony D, Coffey P, Murphy J, O'Hare N, Hamilton D, Freyne P, et al. The discriminant value of semiquantitative SPECT data in mild Alzheimer's disease. J Nucl Med 35, 1450-1455 (1994).
91. Johnson KA, Renshaw PF, Becker JA, Satlin A, Holman BL. Comparison of functional MRI and SPECT in Alzheimer's Disease. Neurology, 45:874S (1995).
92. Reed BR, Jagust WJ, Saeb JP, Ober BA 1989). Memory and regional blood flow in mildly symptomatic Alzheimer's disease. Neurology, 1537-1539 (1989).
93. Pearlson GD, Harris GJ, Powers RE, Barta PE, Camargo EE, Chase GA, et al. Quantitative changes in mesial temporal volume, regional cerebral blood flow, and cognition in Alzheimer's disease. Arch Gen Psychiatry, 402-408 (1992).
94. Harris GJ, Links JM, Pearlson GD, Camargo EE. Cortical circumferential profile of SPECT cerebral perfusion in Alzheimer's disease. Psychiatry Res, 167-180 (1991).
95. Cada A, Gonzalez-Lima F, Rose GM and Bennett MC. Regional brain effects of sodium azide treatment on cytochrome oxidase activity: a quantitative histochemical study. Metab Brain Dis 10: 303-320 (1995).
96. Maas LC, Harris GJ, Satlin A, English CD, Lewis RF, Renshaw PF. Regional cerebral blood volume measure by dynamic susceptibility contrast MR imaging in Alzheimer's disease: a principal components analysis. J Magn Reson Imaging, 215-219(1997).
97. Olazaran J, Linera JA, Santiago, R, Escribano J, Benito-Leon J, Morales JM. Regional correlations between MR imaging perfusion and SPECT in Alzheimer's disease. Neurologia 20 : 240-244(2005).
98. Ogawa S, Lee, TM, Nayak AS and Glynn P. Oxygenation-sensitive contrast in magnetic resonance image of rodent brain at high magnetic fields. Magn Reson Med 14: 68-78 (1990).
99. Ogawa S, Lee TM, Kay AR and Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci U S A 87, 9868-9872 (1990).
100. Ogawa S, Tank DW, Menon R, Ellermann JM, Kim SG, Merkle H, et al. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance scanning. Proc Natl Acad Sci 5951-5955 (1992).
101. van Zijl PC, Eleff SM, Ulatowski JA, Oja JM, Ulug AM, Traystman RJ, et al. Quantitative assessment of blood flow, blood volume and blood oxygenation effects in functional magnetic resonance imaging. Nat Med 4: 159-167(1998).
102. Bandettini PA, Kwong KK, Davis TL, Tootell RB, Wong EC, Fox PT, et al. Characterization of cerebral blood oxygenation and flow changes during prolonged brain activation. Hum Brain Mapp 5: 93-109 (1997).
103. Geddes JW, Monaghan DT, Cotman CW, Lott IT, Kim RC and Chui HC. Plasticity of hippocampal circuitry in Alzheimer's disease. Science 230 : 1179-1181 (1985).
104. Head E, Lott IT, Hof PR, Bouras C, Su JH, Kim R, et al. Parallel compensatory and pathological events associated with tau pathology in middle aged individuals with Down syndrome. J Neuropathol Exp Neurol 62: 917-926(2003).
105. Deller T and Frotscher M. Lesion-induced plasticity of central neurons: sprouting of single fibres in the rat hippocampus after unilateral entorhinal cortex lesion. Prog Neurobiol 53: 687-727.